CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Jagsonpal Pharmaceuticals Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Jagsonpal Pharmaceuticals Ltd
Plot No. 412-415,
Nimai Tower, 3rd Floor, Phase-IV, Udyog
Phone: +91 1126494519p:+91 1126494519 GURGAON, 122015  India Ticker: JAGSNPHARMJAGSNPHARM
Business Summary
Jagsonpal Pharmaceuticals Limited is an India-based pharmaceutical company. The Company is primarily engaged in the manufacturing and trading of pharmaceutical products and active pharmaceutical ingredients (APIs). It operates through the pharmaceuticals business as its segment. The Company operates across therapeutic areas including gynecology, orthopedics, and dermatology. It offers a comprehensive portfolio addressing women’s health, hormonal balance, and pregnancy care. Its brands include Maintane Injections and Tablets, Endoreg, Relufem, Doxypal DR-L, Queezy-ER, Lycored range, Divatrone/SR, FeProtien, Finease, Cycloreg & Fibristone. It is also focused on anti-inflammatory and pain management therapies, with brands such as Indocap, Indocap SR/ P/ EMR, Eclonac P/SP and Metade. Its dermatology portfolio addresses a range of skincare needs, with brands including the Eukroma range, Pru, Sunkroma, Lulyera XL, and the KTC group.
(Source: Company's Website)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20263/31/2026Yes----

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research
2833 Medicinal chemicals and botanical products
5122 Drugs, drug proprietaries, and druggists' sundries

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman Emeritus Rajpal S.Kochhar 68 7/16/2022 7/16/2022
Non-Executive Chairman of the Board HarshaRaghavan 54 1/1/2023 6/29/2022
Chief Financial Officer Nirav N.Vora 10/7/2025 10/7/2025
7 additional Officers and Directors records available in full report.

Business Names
Business Name
507789
Aequitas Healthcare
JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd
Jagsonpal Pharmaceuticals Ltd(NDA)
Yash Pharma Laboratories Private Limited

General Information
Number of Employees: 1,305 (As of 3/31/2026)
Outstanding Shares: 65,957,420 (As of 8/24/2026)
Shareholders: 26,264
Stock Exchange: NSE
Fax Number: +91 1126494708


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Sunday, October 4, 2026